Drug Costs Should Be Basically Borne by Patients under Compassionate Use System: JPMA’s Kuwahara

The Japan Pharmaceutical Manufacturers Association (JPMA) believes that the costs of unapproved drugs provided to patients with no alternative treatments under an envisioned access system should be borne by the patients in principle. The idea for the so-called “compassionate use”...read more